•  
  •  
  •  
  •  

2026-05-21 06:53:43

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • GRSE Launches Next-Gen OPV: Crafted for Vigilance, Built for Victory
  • Muthoot Finance Ranked India's No. 1 Most Trusted Financial Services Brand for 10th Consecutive Year
  • Ampere Magnus G Max by Greaves Electric Mobility Wins 'Family Scooter of the Year' at Times Drive Auto Summit and Awards 2026
  • Eris delivers 11% yoy growth in Domestic Formulations with 37% EBIDTA margin in FY26
  • DevX - Standalone Revenue from Operations grew 34.3% YoY in FY26

Keywords Selected:  DrLalPathLabs

Stock Report

  • Dr Lal PathLabs Limited records revenue of Rs 703 Cr with a growth of 16.6% in Q4 FY26
  • Dr. Lal PathLabs launches SOVAAKA - a next-generation wellness centre blending science, technology, and personalized care
  • Dr. Lal PathLabs Strengthens Autoimmune Diagnosis with India's First Comprehensive Complement Lab
  • Dr Lal PathLabs Limited recommends 1:1 bonus issue
  • Dr Lal PathLabs Limited declares 2nd interim dividend of Rs. 7
  • Dr Lal Path Labs Ltd reports Rs. 150.6 crores consolidated profit in Q2 FY26
  • Dr Lal PathLabs Limited approves acquisition of property in New Delhi
  • Dr. Lal PathLabs Pioneers AI Integration in Cancer Diagnosis in India
  • Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
  • Dr. Lal PathLabs Limited recommends final dividend of Rs. 6
  • Dr. Lal Path Labs Ltd Q4FY25 consolidated PAT jumps to Rs. 154.8 crores
  • Dr. Lal PathLabs becomes South Asia's First Diagnostic Chain to Launch Advanced Test for Amyloidosis
  • Antara, partners with leading diagnostics player Dr. Lal PathLabs to strengthen its geriatric care services
  • Dr. Lal PathLabs Ltd Q2FY25 consolidated net profit increases to Rs. 129.2 crores
  • Dr. Lal PathLabs Limited recommends final dividend of Rs. 6
  • Dr. Lal PathLabs Ltd posts Rs. 84.5 crores consolidated PAT in Q4 FY24
  • Dr Lal Path Labs Ltd Q3FY24 consolidated net profit lower at Rs. 81.3 crores
  • Dr Lal Path Labs Ltd consolidated Q2 FY24 PAT jumps to Rs. 109.3 crores
  • Dr. Lal PathLabs Ltd approves interim dividend of Rs. 6
  • Dr. Lal Path Labs Ltd posts jump in Q1FY24 consolidated PAT to Rs. 82.6 crores
  • Dr. Lal PathLabs Ltd recommends final dividend of Rs. 6
  • Dr. Lal Path Labs Ltd reports QoQ increase in Q4FY23 consolidated net profit to Rs. 56.7 crores
  • Dr. Lal PathLabs Selects Kyndryl for Seamless Cloud Services Management
  • Dr. Lal Path Labs Ltd posts consolidated PAT of Rs. 52.9 crores in Q3FY23

Latest Post

  • GRSE Launches Next-Gen OPV: Crafted for Vigilance, Built for Victory
  • Muthoot Finance Ranked India's No. 1 Most Trusted Financial Services Brand for 10th Consecutive Year
  • Ampere Magnus G Max by Greaves Electric Mobility Wins 'Family Scooter of the Year' at Times Drive Auto Summit and Awards 2026
  • Eris delivers 11% yoy growth in Domestic Formulations with 37% EBIDTA margin in FY26
  • DevX - Standalone Revenue from Operations grew 34.3% YoY in FY26


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025